Published in Anticancer Res on September 22, 1994
Sarcomatoid renal cell carcinoma. A treatable entity. Cancer (1987) 2.12
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol (1990) 1.91
Renal cell cancer: best recipient of tumor-to-tumor metastasis. Urology (1987) 1.55
Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res (2000) 1.52
Fine-needle aspiration cytology of sarcomatoid renal cell carcinoma: a morphologic and immunocytochemical study of 15 cases. Diagn Cytopathol (1993) 1.49
Chemotherapy for small cell carcinoma of prostatic origin. J Urol (1992) 1.46
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer (2001) 1.34
Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer (1987) 1.33
Primary carcinoid of the kidney. Immunohistochemical and ultrastructural studies of five patients. Cancer (1993) 1.29
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol (2000) 1.28
Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol (1989) 1.28
Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer (2001) 1.19
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol (2009) 1.19
Collecting duct carcinoma of the kidney. Br J Urol (1993) 1.18
Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol (1988) 1.17
Genetic abnormalities in men with germ cell tumors. J Urol (1988) 1.07
Association of germ cell tumors and Hodgkin's disease. Urology (1991) 1.06
Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. J Urol (1986) 1.06
Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol (1998) 1.02
Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol (1991) 1.02
Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol (1998) 1.01
The clinical and biological study of androgen independent prostate cancer (AI PCa). Semin Oncol (1994) 0.99
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol (2011) 0.95
Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst (1990) 0.93
Breast cancer in the elderly: histological, hormonal and surgical characteristics. Breast (2007) 0.93
Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. Cancer (1992) 0.93
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res (2001) 0.91
Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer (1997) 0.91
A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer (2000) 0.89
[Psychogenic polydipsia leading to water intoxication]. Harefuah (2000) 0.88
Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol (1995) 0.86
Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer. J Natl Cancer Inst (1991) 0.85
Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol (1994) 0.85
Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol (1995) 0.84
Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. J Clin Oncol (1992) 0.84
Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med (1991) 0.83
Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res (2001) 0.83
Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother (1994) 0.83
Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J Clin Oncol (1990) 0.83
Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep (1985) 0.81
Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract. Ann Oncol (2000) 0.81
Rifampin-resistant meningococcal infection in a patient given rifampin chemoprophylaxis. Am J Infect Control (1988) 0.81
Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol (1999) 0.81
Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. Am J Clin Oncol (1989) 0.81
Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst (1991) 0.81
Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy. Eur J Cancer Clin Oncol (1989) 0.80
Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions. Eur J Clin Pharmacol (2014) 0.80
Serum lactate dehydrogenase isoenzyme 1 as a prognostic predictor for metastatic testicular germ cell tumours. Br J Cancer (2000) 0.80
Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol (2011) 0.79
Nitric oxide synthase inhibitors--a mechanism-based treatment of septic shock. Crit Care Med (1999) 0.79
Serum lactate dehydrogenase isoenzyme 1 and prediction of death in patients with metastatic testicular germ cell tumors. Clin Chem Lab Med (2001) 0.79
Acute delirious state after epsilon-amino caproic acid administration. Clin Toxicol (1979) 0.79
SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res (1995) 0.79
Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol (2011) 0.78
Carboplatin and ifosfamide and selective consolidation in advanced seminoma. Eur J Cancer (1995) 0.78
Interproximal gingival inflammation related to the conversion of a bleeding to a nonbleeding state. J Periodontol (1986) 0.78
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. J Clin Oncol (1996) 0.78
Carpal tunnel syndrome associated with interleukin-2 therapy. Cancer (1996) 0.78
Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients. Eur J Cancer (1993) 0.78
A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma. Oncol Rep (2000) 0.77
Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey. Eur J Cancer Care (Engl) (2013) 0.77
Acute delirious state after epsilon-aminocaproic acid. Lancet (1978) 0.77
Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid. Cancer Chemother Pharmacol (1990) 0.77
Bladder neck involvement at radical prostatectomy: positive margins or advanced T4 disease? Urology (2000) 0.76
Lanthanide chalcogenolate complexes: synthesis and crystal structures of the isoleptic series [Sm(TpMe,Me)2ER] (E = O, S, Se, Te; TpMe,Me = tris-3,5-dimethylpyrazolylborate). Inorg Chem (2000) 0.76
Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens. J Urol (1987) 0.76
Comparative functional analysis of lymphocytes and monocytes from plateletapheresis. Transfusion (1983) 0.76
Simultaneous renal and transitional cell carcinomas in same kidney with subsequent lymph node metastasis: DNA flow cytometric study. Urology (1991) 0.76
Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm Metab Res (1992) 0.76
Inhibition of adamalysin II and MMPs by phosphonate analogues of snake venom peptides. Bioorg Med Chem (1999) 0.76
Malignant hyperthermia in the course of general anesthesia in oral surgery. A case report. J Int Assoc Dent Child (1981) 0.76
Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol (1992) 0.76
Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization. Cancer Chemother Pharmacol (1995) 0.76
A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. Ann Oncol (1995) 0.76
Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology (1998) 0.75
Eosinophilic pleural effusion with high anti-DNA activity as a manifestation of systemic lupus erythematosus. Postgrad Med J (1980) 0.75
Sperm extraction at orchiectomy for testis cancer. Fertil Steril (2001) 0.75
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol (1993) 0.75
Nitric oxide and sepsis. JAMA (1996) 0.75
Salvage chemotherapy in recurrent head and neck cancer: the Institut Gustave Roussy experience. Am J Otolaryngol (1993) 0.75
Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol (1991) 0.75
[Alopecia due to Seroxat therapy]. Harefuah (2000) 0.75